ARIAD Pharma (ARIA) Tops Q1 EPS by 3c; Revises Certain FY16 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AAPL
2. PLTR
3. DOX
4. AMD
5. VRTX
6. CRWD
7. CHKP
8. ON
9. HNGE
10. INSP

Go back to ARIAD Pharma (ARIA) Tops Q1 EPS by 3c; Revises Certain FY16 Guidance

ARIAD Reports First Quarter 2016 Financial Results and Progress on Strategic Review

May 10, 2016 7:35 AM EDT

~Recorded Net Product Revenue of $33.6 million for the first quarter of 2016; growth of 41% from prior year

~Provides guidance for 2016, including strengthened year-end cash position, following announced Incyte transaction:

Global product and royalty revenue of $170 million to $180 million R&D expense of $175 million to $180 million SG&A expense of $120 million to $125 million Year-end cash of $280 million to $290 million

~Conference Call Scheduled Today at 8:30 a.m. ET... More